Literature DB >> 11579012

Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.

A Einarson1, B Fatoye, M Sarkar, S V Lavigne, J Brochu, C Chambers, P Mastroiacovo, A Addis, D Matsui, L Schuler, T R Einarson, G Koren.   

Abstract

OBJECTIVE: Because there are no studies available on the safety of venlafaxine during pregnancy, the authors' goal in this study was to determine whether venlafaxine increases the risk for major malformations.
METHOD: Data on 150 women exposed to venlafaxine during pregnancy in seven pregnancy counseling centers were compared with data from studies of pregnant women who 1) received selective serotonin reuptake inhibitor antidepressants (SSRIs) (N=150) and 2) who received nonteratogenic drugs (N=150).
RESULTS: Among the 150 women who were exposed to venlafaxine during pregnancy, 125 had live births, 18 had spontaneous abortions, and seven had therapeutic abortions; two of the babies had major malformations. There were no significant differences between these women and the two comparison groups on any of the measures analyzed.
CONCLUSIONS: These results suggest that the use of venlafaxine during pregnancy does not increase the rates of major malformations above the baseline rate of 1%-3%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579012     DOI: 10.1176/appi.ajp.158.10.1728

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  35 in total

1.  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction.

Authors:  Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon
Journal:  Arch Gen Psychiatry       Date:  2010-10

Review 2.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

3.  Use of antidepressants during pregnancy and the risk of spontaneous abortion.

Authors:  Hamid Reza Nakhai-Pour; Perrine Broy; Anick Bérard
Journal:  CMAJ       Date:  2010-05-31       Impact factor: 8.262

4.  Diagnosing and Treating Depression During Pregnancy.

Authors:  Christina L Wichman; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2015-04-16

5.  Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal?

Authors:  Althaf Ansary; Samuel Ibhanesebhor; Chikkanayakanahalli Manjunatha
Journal:  Singapore Med J       Date:  2014-04       Impact factor: 1.858

Review 6.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 7.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

8.  Perinatal depression: implications for child mental health.

Authors:  Maria Muzik; Stefana Borovska
Journal:  Ment Health Fam Med       Date:  2010-12

Review 9.  Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis?

Authors:  Markus Treichel; Katharina Schwendener Scholl; Ulf Kessler; Alexander Joeris; Mathias Nelle
Journal:  World J Pediatr       Date:  2009-01-27       Impact factor: 2.764

10.  More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation.

Authors:  Geetha Desai; Girish N Babu; Ravi P Rajkumar; Prabha S Chandra
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.